COMMUNIQUÉS West-GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19/09/2025
NOVATO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare [...]
MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22
19/09/2025
CARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the [...]
PharmAla Files Amended and Restated Preliminary Base Shelf Prospectus
19/09/2025
TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]
GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD
19/09/2025
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 19, 2025 - GENFIT (Nasdaq and Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of patients with [...]
GENFIT annonce l'arrêt de son programme VS-01 dans l'ACLF – le développement de VS-01 est recentré sur l'UCD
19/09/2025
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 19 septembre 2025 – GENFIT (Nasdaq et Euronext: GNFT) , société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de [...]
Hydreight Announces Annual General Meeting Results
19/09/2025
VANCOUVER, British Columbia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS, OTC: HYDTF, FSE: SO6) (“ Hydreight ” or the “ Company ”), is pleased to announce that at the 2025 Annual General [...]
Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans
19/09/2025
WARREN, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today expressed its gratitude to the U.S. Department of Health and Human Services (HHS), Secretary [...]
Kensana Health Lands $120 million from GEM, Fuelling a Global Plant Based Medicine Revolution
19/09/2025
The company expects to list on NASDAQ in Q2 2026 NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Kensana Health Inc. (“Kensana”) today announced it has entered into a share subscription facility of up to $120 million with [...]
Acarpia Farmaceutici et EarlyHealth Group élargissent leur partenariat afin d’améliorer l’accès à CARICOM et au Mexique
19/09/2025
MILAN, 19 sept. 2025 (GLOBE NEWSWIRE) -- Acarpia Farmaceutici S.r.l., un fabricant pharmaceutique italien, et EarlyHealth Group, un prestataire mondial de services pharmaceutiques, ont annoncé l’élargissement de leur [...]
Sironax Named to 2025 Endpoints 11 List of the Most Promising Biotech Startups
19/09/2025
WALTHAM, Mass., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Sironax, a global clinical-stage biotechnology company dedicated to discovering and developing transformative therapies for age-related degenerative diseases, today [...]
TREMFYA (guselkumab) receives positive CHMP opinion for subcutaneous induction regimen in ulcerative colitis, a first for an IL-23 inhibitor
19/09/2025
Recommendation based on the findings from the Phase 3 ASTRO study in ulcerative colitis. 1 , 2 , 3 Guselkumab has the potential to become the first IL-23 inhibitor to offer both subcutaneous and intravenous induction [...]
Signature HealthCARE Committed to Proactive Resident Safety with SafeSpace Global Corporation
19/09/2025
Knoxville, TN, Sept. 19, 2025 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (OTCID:SSGC), a global leader in multimodal AI technology, is pleased to announce an expanded partnership with Signature HealthCARE. [...]
CrazyBulk 2025 | D-BAL, Testo-max , Trenorol , Ultimate Stack Legal Steroids Alternatives launch BY CrazyBulk In USA.
19/09/2025
CrazyBulk introduce safe and effective formula as best Legal Steroids Alternatives for muscle building and bodybuilding without any side effects over the counter supplement new york, Sept. 19, 2025 (GLOBE NEWSWIRE) -- [...]
MomentMD Expands Virtual Clinical Education Platform Amid Growing Provider Shortages and Clinical Rotation Crisis
19/09/2025
With new partnerships and technology updates, the first-of-its-kind platform offers graduate programs immediate solutions to placement bottlenecks MomentMD Logo FORT LAUDERDALE, Fla., Sept. 19, 2025 (GLOBE NEWSWIRE) -- [...]
InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands
19/09/2025
Acquisition of leading cannabis company marks major milestone in InterCure’s commercial expansion strategy, bringing access to premium American brands and state-of-the-art cultivation technologies Transaction comes as [...]
Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner
19/09/2025
GAITHERSBURG, Md., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured new purchase orders from an international government partner for a multi-product supply [...]
Advanced Biomed Inc. Announces Launch of A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery
19/09/2025
[Tainan City], Taiwan, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical [...]
Johnson & Johnson receives positive CHMP opinion of nipocalimab to treat a broad population of antibody-positive patients living with generalised myasthenia gravis (gMG)
19/09/2025
Pending the European Commission’s final decision, nipocalimab could be the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive CHMP [...]
Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities
19/09/2025
Vancouver, Canada, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel [...]

Pages